Page last updated: 2024-10-30

metformin and Guillain-Barre Syndrome

metformin has been researched along with Guillain-Barre Syndrome in 1 studies

Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.

Guillain-Barre Syndrome: An acute inflammatory autoimmune neuritis caused by T cell- mediated cellular immune response directed towards peripheral myelin. Demyelination occurs in peripheral nerves and nerve roots. The process is often preceded by a viral or bacterial infection, surgery, immunization, lymphoma, or exposure to toxins. Common clinical manifestations include progressive weakness, loss of sensation, and loss of deep tendon reflexes. Weakness of respiratory muscles and autonomic dysfunction may occur. (From Adams et al., Principles of Neurology, 6th ed, pp1312-1314)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Paunovic, V1
Peric, S1
Vukovic, I1
Stamenkovic, M1
Milosevic, E1
Stevanovic, D1
Mandic, M1
Basta, I1
Berisavac, I1
Arsenijevic, M1
Bozovic, I1
Nikolic, M1
Stevic, Z1
Trajkovic, V1

Other Studies

1 other study available for metformin and Guillain-Barre Syndrome

ArticleYear
Downregulation of LKB1/AMPK Signaling in Blood Mononuclear Cells Is Associated with the Severity of Guillain-Barre Syndrome.
    Cells, 2022, 09-16, Volume: 11, Issue:18

    Topics: AMP-Activated Protein Kinases; Beclin-1; Down-Regulation; Guillain-Barre Syndrome; Humans; Insulins;

2022